[Indications and limitations of primary systemic therapy for operable breast cancer].
Yamamoto
Naohito
N
Division of Breast Surgery, Chiba Cancer Center.
Suzuki
Masato
M
Tanabe
Naoto
N
D018943:Anthracyclines / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D005260:Female; D005544:Forecasting; D006801:Humans; D019394:Ki-67 Antigen; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D020360:Neoadjuvant Therapy; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab; D016896:Treatment Outcome
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab